Revisiting the metabolic crosstalk between type 2 diabetes and hyperuricemia: Pathophysiological insights and therapeutic perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways and management strategies without systematic review methodology or new empirical data.
PubMed 41197817 · doi:10.1016/j.bbadis.2025.168102
What was done
Narrative synthesis of molecular and clinical literature examining the bidirectional relationship between type 2 diabetes mellitus (T2DM) and hyperuricemia (HUA), covering shared pathogenic mechanisms (oxidative stress, RAAS activation, microbiota metabolites, SLC2A9 genetics) and therapeutic strategies including SGLT2 inhibitors, metformin, urate-lowering therapies, and natural compounds.
What was found
The abstract reports no numerical findings, effect sizes, or statistical metrics. It describes a bidirectional loop wherein elevated uric acid impairs insulin sensitivity and beta-cell function via oxidative stress and inflammation, while insulin resistance reduces renal urate excretion.
Why it matters
Understanding the shared metabolic pathophysiology of T2DM and hyperuricemia provides a rationale for choosing glucose-lowering agents with urate-modulating actions (such as SGLT2 inhibitors) and pursuing integrated management strategies for patients with both conditions.
Limits
This is a narrative review with no original clinical data, systematic search protocol, or quantitative synthesis. The abstract provides no sample sizes or outcome metrics, and causal directions between hyperuricemia and insulin resistance in humans remain complex and unquantified here.
Cited by
- supports There is a feed-forward cycle between insulin and uric acid clearance in the kidneys.